Pharmacist-Led Continuous Glucose Monitoring for Prediabetes: Protocol for a Prospective Cohort Study
- 1Department of Pharmacotherapeutics & Clinical Research University of South Florida Taneja College of Pharmacy Tampa, FL United States
- 2Department of Family Medicine University of South Florida Morsani College of Medicine Tampa, FL United States
- 3University of South Florida College of Public Health Tampa, FL United States
Abstract
Background: Prediabetes represents a critical intervention window to reduce progression to type 2 diabetes. The current standard of care for treatment of prediabetes is weight loss and lifestyle modification, which are both highly effective, although limited by real-world adherence. It is well recognized that continuous glucose monitoring (CGM) improves glycemic and behavioral outcomes in people with diabetes, although outcomes among people with prediabetes are not well described.
Objective: The aim of this study is to evaluate the impact of pharmacist-led CGM on glycemic control and health-related behaviors in adults with prediabetes.
Methods: This study includes a prospective pharmacist-led CGM cohort and a matched retrospective usual-care cohort. Adults aged 18 to 70 years with prediabetes (hemoglobin A1c [HbA1c] 5.7%-6.4%) will be eligible for the prospective cohort if they have a compatible smartphone and no CGM use in the prior 6 months. Participants will receive CGM (Stelo glucose biosensor; Dexcom) and diabetes self-management education and support over 12 weeks. The primary outcome is the change in HbA1c at 12 weeks, compared between groups. Secondary outcomes include CGM-derived metrics, changes in Summary of Diabetes Self-Care Activities scores and 36-Item Short Form Health Survey scores, and CGM-related adverse effects.
Results: This study was funded in 2026. Recruitment is ongoing, and no participants had been enrolled at the time of writing. The planned sample size is 40 participants: 20 prospective CGM participants and 20 retrospective controls. Outcome data are not yet available. The study is expected to be completed in July 2027, and the results are anticipated to be disseminated in December 2027.
Conclusions: This study seeks to evaluate the glycemic impact, behavior change, and safety of pharmacist-led CGM for prediabetes in primary care.
Trial Registration: ClinicalTrials.gov NCT07529366; https://tinyurl.com/33bv7u8c
International Registered Report Identifier (IRRID): PRR1-10.2196/105275
Related
- Continuous glucose monitoring for diabetes prevention in adults with prediabetes: a scoping review
- Glycaemic outcomes of three months of continuous glucose monitoring in children, adolescents and young adults with type 1 diabetes at a Kenyan tertiary hospital: a single-arm prospective study.
- Rational and design of the FREESCA study: A multicenter prospective study assessing the prognostic value of continuous glucose monitoring during hospitalization for acute coronary syndrome
- Prevention of exercise-induced hypoglycemia in 12 patients with type 1 diabetes running the Paris Marathon using continuous glucose monitoring: A prospective, single-center observational study
- Feasibility and acceptability of a remote blood pressure monitoring pharmacist-led telehealth programme in an emergency department transition care clinic: a pilot randomised controlled trial
BibTeX
@article{cowart2026pharmacistled,
title = {{Pharmacist-Led Continuous Glucose Monitoring for Prediabetes: Protocol for a Prospective Cohort Study}},
author = {Kevin Cowart and Raechel T White and Nicholas W Carris and Benedicta O Ansong and Alyssa Hinden and Gwendolyn Clayton and John Petrilli and Eric Coris},
journal = {JMIR Research Protocols},
year = {2026},
month = oct,
doi = {10.2196/105275},
url = {https://doi.org/10.2196/105275},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pharmacist-Led Continuous Glucose Monitoring for Prediabetes: Protocol for a Prospective Cohort Study
AU - Kevin Cowart
AU - Raechel T White
AU - Nicholas W Carris
AU - Benedicta O Ansong
AU - Alyssa Hinden
AU - Gwendolyn Clayton
AU - John Petrilli
AU - Eric Coris
PY - 2026
DA - 2026/10/15
JO - JMIR Research Protocols
DO - 10.2196/105275
UR - https://doi.org/10.2196/105275
AB - Background: Prediabetes represents a critical intervention window to reduce progression to type 2 diabetes. The current standard of care for treatment of prediabetes is weight loss and lifestyle modification, which are both highly effective, although limited by real-world adherence. It is well recognized that continuous glucose monitoring (CGM) improves glycemic and behavioral outcomes in people with diabetes, although outcomes among people with prediabetes are not well described. Objective: The aim of this study is to evaluate the impact of pharmacist-led CGM on glycemic control and health-related behaviors in adults with prediabetes. Methods: This study includes a prospective pharmacist-led CGM cohort and a matched retrospective usual-care cohort. Adults aged 18 to 70 years with prediabetes (hemoglobin A1c [HbA1c] 5.7%-6.4%) will be eligible for the prospective cohort if they have a compatible smartphone and no CGM use in the prior 6 months. Participants will receive CGM (Stelo glucose biosensor; Dexcom) and diabetes self-management education and support over 12 weeks. The primary outcome is the change in HbA1c at 12 weeks, compared between groups. Secondary outcomes include CGM-derived metrics, changes in Summary of Diabetes Self-Care Activities scores and 36-Item Short Form Health Survey scores, and CGM-related adverse effects. Results: This study was funded in 2026. Recruitment is ongoing, and no participants had been enrolled at the time of writing. The planned sample size is 40 participants: 20 prospective CGM participants and 20 retrospective controls. Outcome data are not yet available. The study is expected to be completed in July 2027, and the results are anticipated to be disseminated in December 2027. Conclusions: This study seeks to evaluate the glycemic impact, behavior change, and safety of pharmacist-led CGM for prediabetes in primary care. Trial Registration: ClinicalTrials.gov NCT07529366; https://tinyurl.com/33bv7u8c International Registered Report Identifier (IRRID): PRR1-10.2196/105275
SN - 1929-0748
ER -